Jun 20 |
Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
|
Jun 6 |
Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
|
May 29 |
Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
|
May 20 |
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
|
Apr 24 |
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
|
Apr 10 |
Kiromic BioPharma files to withdraw registration statement
|
Apr 2 |
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
|
Mar 19 |
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
|
Mar 8 |
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
|
Mar 5 |
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
|